Skip to content

DAAAK Pharma Int. AS

Registry code (registrikood) 12864378Public limited company (Aktsiaselts)VAT EE101908124Activity (EMTAK 46461): Ravimite ja muude apteegikaupade hulgimüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€7.6M
▼ 28.4% vs 2024
Profit before tax (2025)
€60k
Employees, FTE (2025)
11
State taxes paid, last 4 quarters
€72k

Revenue, profit and employees, 2019–2025

€3.6M2019€4.2M2020€4.9M2021€4.1M2022€17.4M2023€10.6M2024€7.6M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€3,569,799€60,635€73,990€882,69511
2020€4,249,009€213,194€126,982€794,16313
2021€4,857,922-€172,087-€198,571€535,59210
2022€4,088,283€455,204€410,304€695,88610
2023€17,441,725€2,540,115€2,489,353€2,785,23911
2024€10,570,895-€229,980-€296,257€2,488,98215
2025€7,565,196€95,712€60,392€2,549,37411

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€723,609€1,704,863€790,080€32,088€882,695
2020€452,067€1,601,990€786,435€21,392€794,163
2021€656,559€1,977,424€1,432,081€9,751€535,592
2022€455,496€2,823,971€2,128,085€0€695,886
2023€1,594,270€8,720,726€5,935,487€0€2,785,239
2024€1,200,081€3,242,530€753,548—€2,488,982
2025€1,611,784€3,295,694€746,320—€2,549,374

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€11,327€11,793€1,087,9163
2022 Q2€11,976€9,075€1,872,7853
2022 Q3€27,135€9,352€59,4353
2022 Q4€23,966€9,366€1,823,5433
2023 Q1€9,198€9,556€4,073,2233
2023 Q2€14,467€10,006€5,143,0573
2023 Q3€16,156€10,071€3,462,3133
2023 Q4€11,921€12,430€6,133,8753
2024 Q1€33,886€22,558€5,647,5454
2024 Q2€31,186€21,432€1,854,6684
2024 Q3€17,271€14,698€3,258,0704
2024 Q4€14,334€14,692€3,443,5424
2025 Q1€69,880€17,611€2,756,6074
2025 Q2€16,845€15,565€2,372,1034
2025 Q3€15,226€15,726€5,243,8144
2025 Q4€18,479€17,375€3,001,9264
2026 Q1€19,685€20,013€5,943,6474
2026 Q2€17,175€17,341€2,781,7434
2026 Q3€16,580€17,083€4,945,4704

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), DAAAK Pharma Int. AS reported revenue of €7,565,196.

The company closed the 2025 financial year with a net profit of €60,392.

Revenue decreased by 28.4% from €10,570,895 in 2024 to €7,565,196 in 2025.

Revenue grew at a compound annual rate of 13.3% between 2019 and 2025.

Equity accounted for 77.4% of total assets of €3,295,694 at the end of the 2025 reporting period.

With 11 full-time-equivalent employees in 2025, revenue per employee was €687,745.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, DAAAK Pharma Int. AS reported €16,672,786 in turnover.

EMTA recorded 4 employees for the quarter ending Q3 2026, compared with 11 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.